Different Options for Aspirin Hypersensitivity in PCI

Original Title: Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention. A Survey and Systematic Review. Reference: Bianco M et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002896.

The follow up strategy for aspirin hypersensitive patients undergoing PCI remains unclear.

A systematic search included 283 patients from 11 studies. Primary end point was discharge with aspirin, while adverse events rate was the secondary end point.

Only one of the studies performed an endovenous desensitization protocol that was highly effective (98%) and saw few adverse events, compared to the rest of protocols with oral administration of escalating doses of aspirin.

There were no significant differences among the oral desensitization protocols (more vs. less fractioned) in terms of efficacy, while the incidence of rash and angioedema were higher in those protocols using less than 6 doses escalation.

During follow up, 65% of physicians managed aspirin hypersensitivity by changing the therapeutic regimen (e.g. Clopidogrel as monotherapy).
Despite prior safety data, desensitization protocols were used only by 42% of cardiologists.

Conclusion
The existing protocols to treat aspirin hypersensitivity are safe and effective and represent a viable option for patients that need dual antiaggregation therapy and are allergic to aspirin.

Editorial Comment
One of the desensitization protocols is the oral administration of 6 escalating doses of aspirin (1, 5, 10, 20, 40 and 100 mg) in 5.5 hours with or without simultaneous administration of corticoids and antihistamines. According to this study, consecutive doses should not be less than 6, because of the higher chance of angioedema and rash.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...